Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTTSOUD)

• DTT Name: Candida Cytochrome P450 51 (Candi ERG11) DTT Info
• Gene Name: Candi ERG11

Molecule-Related Drug & Molecule List

16 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[1]
Butoconazole	DM8SY60	Candidiasis	1F23	Approved	[2]
Econazole	DMFSWGH	Cutaneous candidiasis	1F23.14	Approved	[3]
Efinaconazole	DMFA9MV	Fungal infection	1F29-1F2F	Approved	[4]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[5]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[5]
Ketoconazole	DMPZI3Q	Blastomycosis	1F22	Approved	[6]
Luliconazole	DMT73J8	Tinea corporis	1F28.Y	Approved	[7]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[5]
Oteseconazole	DM7R145	Vulvovaginal Candidiasis	1F23.10	Approved	[8]
Oxiconazole	DME7KRM	Tinea corporis	1F28.Y	Approved	[9]
Posaconazole	DMUL5EW	Aspergillosis	1F20	Approved	[10]
Sertaconazole	DM1A9XO	Fungal infection	1F29-1F2F	Approved	[11]
Terconazole	DMJ13KI	Candidiasis	1F23	Approved	[12]
Tioconazole	DMNYPGS	Onychomycosis	EE12.1	Approved	[13]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[5]

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHLORIDE	DM1TJXA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[14]
E-1224	DMLS269	Fungal infection	1F29-1F2F	Phase 2	[15]
EcoNail	DM1LDIP	Fungal infection	1F29-1F2F	Phase 2	[16]
Pramiconazole	DMBH7XI	Dermatological disease	DA24.Y	Phase 2	[17]
Embeconazole	DM6AMKZ	Fungal infection	1F29-1F2F	Phase 1	[18]
Genaconazole	DMWR93D	Fungal infection	1F29-1F2F	Phase 1	[19]
VT-1598	DM8HBW0	Coccidioidomycosis	1F25	Phase 1	[20]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abafungin	DM09GSW	Fungal infection	1F29-1F2F	Discontinued in Phase 3	[21]
AZALANSTAT	DMV1ES3	Hyperlipidaemia	5C80	Discontinued in Phase 2	[22]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANALOGUE A	DM5JN3P	Discovery agent	N.A.	Investigative	[23]
citric acid	DM80YI7	Discovery agent	N.A.	Investigative	[24]
CP-320626	DMY8O0B	Discovery agent	N.A.	Investigative	[23]

References

• [1] Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
• [2] Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5.
• [3] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [4] Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73.
• [9] Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
• [10] A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
• [11] Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.
• [12] Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
• [13] Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
• [14] Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22.
• [15] Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242.
• [16] Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45.
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] CS-758. Antifungal lanosterol 14alpha-demethylase inhibitor, 003, vol28, no3, 217-223.
• [19] New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47.
• [20] The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis. Med Mycol. 2020 Jun 1;58(4):505-513.
• [21] Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol. 2005 Nov;144(1):68-75.
• [22] Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol. 1995 Aug 8;50(4):529-44.
• [23] Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500.
• [24] Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71.